Publications

2015

Innovating a Canadian innovation ecosystem. Policy Options. http://policyoptions.irpp.org/issues/clearing-the-air/gold-et-al/

The media and access issues: content analysis of Canadian newspaper coverage of health policy decisions. Orphanet Journal of Rare Diseases. http://www.ojrd.com/content/pdf/s13023-015-0320-z.pdf

The gene patent controversy on Twitter: a case study of Twitter users’ responses to the CHEO lawsuit against Long QT gene patents. BMC Medical Ethicshttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548905/pdf/12910_2015_Article_49.pdf

The commercialization of university-based research: Balancing risks and benefits. BMC Medical Ethics. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605102/pdf/12910_2015_Article_64.pdf

Marginally Scientific? Genetic Testing of Children and Adolescents for Lifestyle and Health Promotion. Journal of Law and the Biosciences. http://jlb.oxfordjournals.org/content/early/2015/11/16/jlb.lsv038.full.pdf

Current Practices and Reform Proposals for the Regulation of Advanced Medicinal Products in Canada. Regenerative Medicinehttp://www.ncbi.nlm.nih.gov/pubmed/26237706

The Obesity Gene and the (Misplaced) Search for a Personalized Approach to Our Weight Gain Problems. Wake Forest Journal of Law and Policyhttp://lawpolicyjournal.law.wfu.edu/files/2015/03/5-Caulfield_Final.pdf

Commercialisation of Human Genetic Research. Encyclopedia of Life Scienceshttp://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0005651.pub2/abstract

Use and Misuse of Material Transfer Agreements: Lessons from Research, Repositories, and Litigation. PLoS Biology. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315468/pdf/pbio.1002060.pdf

2014

Theory Testing and Implication in Clinical Trials. Philosophy of Sciencehttp://philsci-archive.pitt.edu/11045/1/biomarker_theory_testing-psa.pdf

Are Outcome-Adaptive Allocation Trials Ethical? Clinical Trials. http://ctj.sagepub.com/content/12/2/102

Physician Liability and Non-Invasive Prenatal Testing. J Obstet Gynaecol Can. http://www.jogc.ca/abstracts/full/201410_Commentary_1.pdf

Science Powers Commerce: Mapping the Language, Justifications, and Perceptions of the Drive to Commercialize in the Context of Canadian Research. Canadian Journal of Comparative and Contemporary Lawhttp://www.cjccl.ca/science-powers-commerce/

Newspaper Coverage of Biobanks. Peer J. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121587/

Defining medical necessity in an age of personalised medicine: A view from Canada. Bioessays. http://www.ncbi.nlm.nih.gov/pubmed/25059840

It’s not all in the genes. Policy Options. http://policyoptions.irpp.org/issues/old-politics-new-politics/caulfield/

Direct to Consumer Genetic Testing in Canada: should we be concerned. Healthy Debate. http://healthydebate.ca/opinions/direct-consumer-genetic-testing

Some Inconsistencies in NICE’s Consideration of Social Values. Pharmacoeconomics. http://link.springer.com/article/10.1007%2Fs40273-014-0204-4

Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. Journal of Cancer Policy. http://www.sciencedirect.com/science/article/pii/S2213538314000186

Value-Engineered Translation: Developing Biotherapeutics that align with health-system needs. American Journal of Managed Care: Evidence-Based Diabetes Management 20 (Special Issue 10). http://www.ajmc.com/publications/evidence-based-diabetes-management/2014/july-august-2014/Value-Engineered-Translation-Developing-Biotherapeutics-That-Align-With-Health-System-Needs

Should patients be told about incidental findings from genetic testingHealthy Debate. http://healthydebate.ca/2014/07/topic/genetic-testing-incidental-findings

The Right to Control and Access Genetic Material: Does McInerney Offer a Way Out of the Consent/Withdrawal Conundrum? UBC Law Review. http://www.hli.ualberta.ca/~/media/hli/Research/Docs/2013-09-15_McInerney_website.pdf

Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. PharmacoEconomics. http://link.springer.com/article/10.1007%2Fs40273-014-0134-1

Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice? PharmacoEconomicshttp://www.ncbi.nlm.nih.gov/pubmed/24599785

Human genetic research, race, ethnicity and the labeling of populations: recommendations based on an interdisciplinary workshop in Japan. BMC Medical Ethics. http://www.biomedcentral.com/1472-6939/15/33

Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. PharmacoEconomics. http://www.ncbi.nlm.nih.gov/pubmed/24488576

Policy recommendations for addressing privacy challenges associated with cell-based research and interventions. BMC Medical Ethics. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914710/

2013

Reflections on the Cost of “Low-Cost” Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology. http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001699

Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of Health Systems. Stem Cells and Development. http://online.liebertpub.com/doi/pdfplus/10.1089/scd.2013.0398

The Paradoxes of Pop Science. Policy Options. Sept – Oct 2013 http://www.irpp.org/en/po/the-age-of-man/the-paradoxes-of-pop-science/

Pressing the Pause Button. Cure Magazine. Sept 2013. http://www.curetoday.com/

Direct-to-consumer genetic testing — where should we focus the policy debate? Medical Journal of Australia. https://www.mja.com.au/journal/2013/198/9/direct-consumer-genetic-testing-where-should-we-focus-policy-debate

Reflections on the Cost of “Low-Cost” Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818164/

Ethics and Genomic Incidental Findings. Science. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772710/

Policy Uncertainty, Sequencing, and Cell Lines. G3 Genomes. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737160/

Angelina Jolie’s faulty gene: newspaper coverage of a celebrity’s preventive bilateral mastectomy in Canada, the United States, and the United Kingdom. Genetics in Medicinehttp://www.ncbi.nlm.nih.gov/pubmed/24357851

A Canadian screening program for hepatitis C: Is now the time? CMAJ onlinehttp://www.cmaj.ca/content/185/15/1325/reply